Home › Funds › Euclidean Capital LLC › SRZN
Euclidean Capital LLC position in SRZN
SURROZEN INC · Health Care
Euclidean Capital LLC reported holding 87,696 shares of SRZN (SURROZEN INC) in its Q2 2026 13F filing — a position valued at US$2.3M, representing 0.52% of its reported portfolio and ranking #9 among its reported holdings. Euclidean Capital LLC has disclosed SRZN holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Euclidean Capital LLC's SRZN position evolved
Euclidean Capital LLC first disclosed a stake in SRZN in Q3 2023 at 1,315,463 shares (US$645K). The position peaked in Q1 2026 at 87,696 shares, worth US$2.6M. Across 12 filings, Euclidean Capital LLC increased the stake 0 time(s), trimmed it 1 time(s) and left it unchanged 10 time(s). The most recent filing (Q2 2026) shows 87,696 shares valued at US$2.3M. Notable position changes include a 93% trim in Q4 2023 (shares rose 67% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 1.32M | $644.58K | New |
| Q4 2023 | 87.70K | $824.34K | Reduce |
| Q1 2024 | 87.70K | $1.38M | Hold |
| Q2 2024 | 87.70K | $960.27K | Hold |
| Q3 2024 | 87.70K | $1.05M | Hold |
| Q4 2024 | 87.70K | $1.26M | Hold |
| Q1 2025 | 87.70K | $1.02M | Hold |
| Q2 2025 | 87.70K | $784.00K | Hold |
| Q3 2025 | 87.70K | $1.13M | Hold |
| Q4 2025 | 87.70K | $1.98M | Hold |
| Q1 2026 | 87.70K | $2.55M | Hold |
| Q2 2026 | 87.70K | $2.28M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About SRZN and 13F data
SRZN (SURROZEN INC) is a Health Care company. 51 other funds we track also report a position in SRZN — the largest reported positions include Column Group LLC (US$49.7M), TCG Crossover Management, LLC (US$38.2M), Boxer Capital Management, LLC (US$27.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding SRZN
- Column Group LLC 1.92M sh · $49.74M · Q2 2026
- TCG Crossover Management, LLC 1.47M sh · $38.23M · Q2 2026
- Boxer Capital Management, LLC 1.11M sh · $26.96M · Q2 2026
- Venrock Adviser, LLC 632.93K sh · $16.42M · Q2 2026
- STEMPOINT CAPITAL LP 602.80K sh · $13.79M · Q2 2026
- Spruce Street Capital LP 432.04K sh · $11.21M · Q2 2026
- Kalehua Capital Management LLC 385.18K sh · $10.00M · Q2 2026
- 5AM Venture Management, LLC 271.25K sh · $7.04M · Q2 2026
- Vivo Capital, LLC 260.00K sh · $6.75M · Q2 2026
- ACUTA CAPITAL PARTNERS, LLC 173.40K sh · $4.50M · Q2 2026
- REGENTS OF THE UNIVERSITY OF CALIFORNIA 133.21K sh · $3.46M · Q2 2026
More on Euclidean Capital LLC
FAQ
How long has Euclidean Capital LLC held SRZN?
Euclidean Capital LLC has disclosed SRZN holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
What is Euclidean Capital LLC's current position in SRZN?
As of Q2 2026, Euclidean Capital LLC holds 87.70K shares of SRZN (SURROZEN INC), valued at $2.28M, representing 0.52% of its reported portfolio and ranking #9.
Has Euclidean Capital LLC been buying or selling SRZN?
In the latest 13F filing (Q2 2026), Euclidean Capital LLC held unchanged its position in SRZN. The position peaked in Q1 2026 at 87.70K shares.
Which other funds hold SRZN?
Other major institutional holders of SRZN include Column Group LLC, TCG Crossover Management, LLC, Boxer Capital Management, LLC, among 51 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.